Press release
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
ARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"\nARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity\n\nARCT-154, Arcturus’ STARR™ mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers against all variants tested in primates, including the Delta variant\n\nARCT-154 to begin staged Phase 3 study in Vietnam; potential for EUA in December\n\nInvestor conference call at 4:30 p.m. ET today\n\n SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2021 and provided corporate updates.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005702/en/Non-Human Primate (NHP) data collected one month after second dose of 7.5 mcg; analysis of NHP serum was performed using non-replicating vesicular stomatitis virus pseudo-typed with the spike protein of the SARS-CoV-2 variants of concern indicated. Titers (geometric mean) were determined by calculating the dilution that resulted in 50% inhibition of cells expressing GFP encoded by the pseudovirus, a surrogate of virus infection. Error bars indicate geometric standard deviation. (Photo: Business Wire)\n“This has been an exceptionally productive period where Arcturus has made substantial progress with our mRNA-based vaccine and therapeutic platforms. We are excited about the imminent initiation of the global Phase 3 vaccine trial of ARCT-021, which is funded by a global entity. We made excellent progress advancing and partnering ARCT-154, our next generation vaccine, which targets SARS-CoV-2 variants, including the rapidly expanding and highly transmissible Delta variant. In addition to the progress with our vaccine franchise, we’ve also advanced our therapeutics pipeline, with the approval of a multiple dose Phase 2 study with ARCT-810, our systemically administered mRNA therapeutic candidate for individuals with OTC deficiency,” said Joseph Payne, President and CEO of Arcturus.\n\nRecent Corporate Highlig...